Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe/Daiichi Sankyo) Drug Analysis 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Drug Analysis: Invokana" drug pipelines has been added to ResearchAndMarkets.com's offering.

Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe/Daiichi Sankyo) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism. They prevent filtered glucose from being reabsorbed in the kidney rather than actively facilitating glucose filtration and excretion. Due to this distinct mechanism of action, when SGLT-2 inhibitors are used as monotherapy they do not lower glucose to unsafe levels and thus avoid the risk of hypoglycemia.

Key Topics Covered:

1 Product Profiles

  • Invokana: Diabetic nephropathy
  • Invokana: Diabetes type 2

List of Figures

Figure 1: Invokana for diabetic nephropathy - SWOT analysis

Figure 2: The author's drug assessment summary for Invokana in diabetic nephropathy

Figure 3: The author's drug assessment summary for Invokana in diabetic nephropathy

Figure 4: Invokana for type 2 diabetes - SWOT analysis

Figure 5: Drug assessment of Invokana

Figure 6: Drug assessment scorecard for Invokana compared to Januvia

Figure 7: Invokana sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016-25

Figure 8: Invokamet sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016-25

List of Tables

Table 1: Invokana drug profile

Table 2: Invokana Phase III trial in diabetic nephropathy

Table 3: Invokana drug profile

Table 4: Overview of pivotal trial data for Invokana in diabetes

Table 5: Key endpoint data from the CANVAS trial program

Table 6: Invokana sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016-25

Table 7: Invokamet sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016-25

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/zbgfs5/invokana?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs